These Analysts Increase Their Forecasts On Gilead Sciences After Upbeat Q3 Results

Gilead Sciences, Inc. (NASDAQ:GILD) reported better-than-expected earnings for the third quarter on Thursday.

The company posted quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.19 per share. The company reported quarterly sales of $8.300 billion which beat the analyst consensus estimate of $7.809 billion.

Gilead Sciences cut its FY2026 adjusted EPS guidance from $(0.65)-$(0.30) to $(1.20)-$(0.85), while increasing sales guidance from $30.100 billion-$30.400 billion to $31.000 billion-$31.300 billion.

“Gilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026. Our HIV business grew 18% and HIV prevention sales nearly doubled year-over-year. With multiple ongoing and potential launches across HIV and Oncology, important progress in Inflammation and a disciplined operating model, Gilead is well positioned for business growth and impact for patients.”

Gilead shares rose 4.1% to $172.35 in pre-market trading

These analysts made changes to their price targets on Gilead following earnings announcement.

• Needham analyst Joseph Stringer maintained the stock with a Buy and raised the price target from $170 to $200.
• Cantor Fitzgerald analyst Carter Gould maintained the stock with an Overweight rating and boosted the price target from $155 to $175.

Considering buying GILD stock? Here’s what analysts think:

Photo via Shutterstock